Lupus erythematosus - Ilupus Erythematosus
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Kubonakala ngathi i-erythema emfusa kancinci.
Irhashalala yebhabhathane edla ngokuvela ebusweni.
References
Ukuchonga kunye nokuhlelwa kwe- cutaneous lupus erythematosus (CLE) kubangela imingeni yokuxilongwa, ukwahlula kwi- systemic lupus erythematosus ngokubandakanyeka kwesikhumba. Uphononongo lwakutsha nje lunika ukukhanya kwimfuza, indalo esingqongileyo, kunye nemiba ye-immunoloji ephantsi kwe-CLE. Ukufakwa kweziyobisi ngokukodwa kuye kwavela njengenye yezona zinto zibangela i-CLE. Unyango lubandakanya unyango lwe-topical kunye nolwenkqubo, kubandakanywa ne-biologicals ethembisayo (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , kunye nokusebenza okubonakalisiweyo kulingo lwezonyango.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) ibandakanya imiba yolusu eyahlukeneyo, eminye yayo inokunxulumana neengxaki zempilo ezibanzi. Ihlelwe ngokweendidi ezahlukeneyo, ezinje nge acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . I-CCLE iquka discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus liqela lezifo ezizimelayo ezinokuchaphazela amalungu ahlukeneyo omzimba. Ezinye iintlobo, njenge systemic lupus erythematosus (SLE) , zinempembelelo kumalungu amaninzi, ngelixa ezinye, njenge cutaneous lupus erythematosus (CLE) , zichaphazela kakhulu ulusu. Sihlela iindidi ezahlukeneyo ze-CLE ngokusekwe kumxube weempawu zeklinikhi, uvavanyo lwethishu, kunye novavanyo lwegazi, kodwa kukho umahluko omkhulu phakathi kwabantu. Iingxaki zolusu zihlala zivela ngenxa yezinto ezifana nokuvezwa lilanga, ukutshaya, okanye amayeza athile.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Unobangela we ilupus erythematosus (lupus erythematosus) awucaci. Kumawele afanayo, ukuba elinye liyachaphazeleka kukho amathuba angama-24% elinye libe nawo. Iihomoni zesini zabasetyhini, ukukhanya kwelanga, ukutshaya, ukunqongophala kwevithamin D, kunye nosulelo oluthile nazo zikholelwa ukuba zonyusa umngcipheko.
Unyango lunokubandakanya ii-NSAID, i-corticosteroids, i-immunosuppressants, i-hydroxychloroquine, kunye ne-methotrexate. Nangona i-corticosteroids iyasebenza, ukusetyenziswa kwexesha elide kubangela iziphumo ezibi.